Supplementary Figure S5 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

Figure S5. Comparison of PFS stratified by the different timepoint post-treatment residual status either of plasma ctDNA or MFC at (A) C2D1, (B) C3D1 and (C) C4D1 post-treatment. ctDNA neg-MFC neg was defined as the VAF of mutation being negative for ctDNA and MRD being negative for MFC at each timepoint. ctDNA pos-MFC neg was defined as the VAF of mutation >0.01% for ctDNA and MRD being negative for MFC at each timepoint. ctDNA pos-MFC pos was defined as the VAF of mutation >0.01% for ctDNA and immunophenotype ≥10−4 myeloblasts for MFC at each timepoint. MFC, multiparameter flow cytometry; C2D1, Cycle 2 day 1; C3D1, Cycle 3 day 1; C4D1, Cycle 4 day 1